Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients
top of page
Search
Recent Posts
See AllInterim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel da
- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- - Commenced exclusive distribut
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD, MBA, FAAD, as Chief Medical Officer. Dr. Rico has over
bottom of page